BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company that develops medicines for people with genetically defined conditions. Founded in 1997 and based in San Rafael, California, the company has eight commercial therapies. In 2025, BioMarin achieved $3.2 billion in total revenues, with a significant contribution from VOXZOGO. The company focuses on developing and commercializing innovative therapies for patients with serious and life-threatening rare diseases and medical conditions through internal research, partnerships, and acquisitions. BioMarin conducts strategic portfolio assessments of research and development programs to evaluate scientific merit, commercial success opportunity, and potential value creation for stockholders, which may lead to the discontinuation of programs that do not meet development thresholds. In December 2025, BioMarin entered into a definitive agreement to acquire Amicus Therapeutics, Inc. for $14.50 per share in an all-cash transaction totaling approximately $4.8 billion. This acquisition is expected to add two new therapies for Fabry disease and late-onset Pompe disease to BioMarin's commercial portfolio. The transaction is expected to close in the second quarter of 2026 and will be financed through cash on hand and approximately $3.7 billion of non-convertible debt financing.